FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Truffle Capital S.A.S. 		2. Issuer Name and Ticker or Trading Symbol

Altimmune, Inc. [ ALT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

5, RUE DE LA BAUME 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/13/2017
(Street)

PARIS, I0 75008
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, par value $0.0001   12/13/2017     J (1)    16018   A   (1) 141163   I   See Footnote   (2) (3)
Common Stock, par value $0.0001   12/13/2017     J (1)    21357   A   (1) 88163   I   See Footnote   (2) (4)
Common Stock, par value $0.0001   12/13/2017     J (1)    16018   A   (1) 38436   I   See Footnote   (2) (5)
Common Stock, par value $0.0001   12/15/2017     J (6)    4337   A   (6) 145500   I   See Footnote   (2) (3)
Common Stock, par value $0.0001   12/15/2017     J (6)    5784   A   (6) 93947   I   See Footnote   (2) (4)
Common Stock, par value $0.0001   12/15/2017     J (6)    4337   A   (6) 42773   I   See Footnote   (2) (5)
Common Stock, par value $0.0001                  416043   I   See Footnote   (2) (7)
Common Stock, par value $0.0001                  230103   I   See Footnote   (2) (8)
Common Stock, par value $0.0001                  183690   I   See Footnote   (2) (9)
Common Stock, par value $0.0001                  179359   I   See Footnote   (2) (10)
Common Stock, par value $0.0001                  151441   I   See Footnote   (2) (11)
Common Stock, par value $0.0001                  116654   I   See Footnote   (2) (12)
Common Stock, par value $0.0001                  105804   I   See Footnote   (2) (13)
Common Stock, par value $0.0001                  1774   I   See Footnote   (2) (14)
Common Stock, par value $0.0001                  1255   I   See Footnote   (2) (15)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Convertible Preferred Stock   $2.67   (16) 12/13/2017     J   (1)       22.7661    8/21/2017   8/15/2018   Common Stock, par value $0.0001   8527     (1) 159.3618   I   See Footnote   (2) (3)
Series B Convertible Preferred Stock   $2.67   (16) 12/13/2017     J   (1)       30.3547    8/21/2017   8/15/2018   Common Stock, par value $0.0001   11369     (1) 212.4817   I   See Footnote   (2) (4)
Series B Convertible Preferred Stock   $2.67   (16) 12/13/2017     J   (1)       22.7661    8/21/2017   8/15/2018   Common Stock, par value $0.0001   8527     (1) 159.3618   I   See Footnote   (2) (5)

Explanation of Responses:
(1)  Pursuant to the terms of the Series B Convertible Preferred Stock (the "Preferred Stock"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock") at the installment conversion price of $1.4213 per share of Common Stock.
(2)  Truffle Capital S.A.S., a French societe par actions simplifiee, is the fund manager for each of the funds listed in the following footnotes and as such manages and controls all voting and dispositive rights to shares held by each such fund. Philippe Pouletty, Bernard-Louis Roques and Henri Moulard may be deemed to possess voting and dispositive control over the shares held by funds managed by Truffle Capital S.A.S. and may be deemed to have indirect beneficial ownership of such shares. Each of these individuals disclaims beneficial ownership of such shares, except with respect to any pecuniary interest therein.
(3)  Held directly by UFF Innovation 14 FCPI, a FCPI (Fonds Commun de Placement dans l'Innovation), which is a tax efficient French collective investment fund.
(4)  Held directly by UFF Innovation 15 FCPI, a FCPI.
(5)  Held directly by Truffle Fortune 4 FCPI, a FCPI.
(6)  Pursuant to the terms of the Series B Convertible Preferred Stock (the "Preferred Stock"), the Issuer converted the Preferred Stock into shares of the Issuer's common stock, par value $0.0001 per share (the "Common Stock") at the installment conversion price of $1.3910 per share of Common Stock.
(7)  Held directly by UFF Innovation 5 (UFF5) FCPI, a FCPI.
(8)  Held directly by UFF Innovation 17 FCPI, a FCPI.
(9)  Held directly by Truffle Cap II (TCII) FCPR, a FCPR (Fonds Commun de Placement a Risque), which is a French venture capital fund for institutional subscribers.
(10)  Held directly by Truffle Fortune 6 FCPI, a FCPI.
(11)  Held directly by UFF Innovation 16 FCPI, a FCPI.
(12)  Held directly by Truffle Fortune 5 FCPI, a FCPI.
(13)  Held directly by Truffle InnoCroissance 2015 FCPI, a FCPI.
(14)  Held directly by Europe Innovation 2006 (E106) FCPI, a FCPI.
(15)  Held directly by Europe Innovation 2004 (E104) FCPI, a FCPI.
(16)  The Issuer's Preferred Stock is convertible at any time at the option of the holder into shares of the Issuer's Common Stock, subject to certain restrictions, at an initial conversion price of $2.67 per share and a stated amount of $1,000 per share.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Truffle Capital S.A.S.
5, RUE DE LA BAUME
PARIS, I0 75008
X


Signatures
/s/ Ori Solomon, Attorney in fact for Truffle Capital S.A.S. 12/15/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Altimmune Charts.
Altimmune (NASDAQ:ALT)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Altimmune Charts.